Marginal Zone Lymphoma

Authors:
Omid S. Shaye From the Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.

Search for other papers by Omid S. Shaye in
Current site
Google Scholar
PubMed Close
 MD
and
Alexandra M. Levine From the Division of Hematology, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.

Search for other papers by Alexandra M. Levine in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 4: Issue 3
Online Publication Date:
Mar 2006
DOI:
https://doi.org/10.6004/jnccn.2006.0026
Full access

Marginal zone lymphomas (MZLs) comprise 3 distinct entities: extranodal MZL of mucosa-associated lymphoid tissue (MALT), splenic MZL, and nodal MZL. Gastric MALT lymphoma is the most common extranodal MZL and often develops as a result of chronic Helicobacter pylori gastritis. Such cases frequently respond to antibiotics directed against H. pylori. Antigen-driven lymphomatous disease can also be seen in the association of Borrelia burgdorferi with MALT lymphoma of the skin, Chlamydia psittaci with MALT lymphoma of the ocular adnexa, Campylobacter jejuni with immunoproliferative disease of the small intestine, and hepatitis C with splenic MZL. This article discusses the pathogenesis and clinical features of MZL and the treatment options available to patients.

Correspondence: Alexandra M. Levine, MD, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Room 3468, Los Angeles, CA 90033. E-mail: alevine@usc.edu
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Harris NL, Jaffe ES, Stein H et al.. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994;84:1361–1392.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    Jaffe ES, Harris NL, Stein H et al.. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press; 2001:351.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89:3909–3918.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue: a distinctive type of B-cell lymphoma. Cancer 1983;52:1410–1416.

  • 5.

    Jonsson V, Wiik A, Hou-Jensen K et al.. Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders. J Intern Med 1999;245:277–286.

  • 6.

    Zucca E, Bertoni F, Roggero E et al.. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid tissue lymphoma of the stomach. N Engl J Med 1998;338:804–810.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR et al.. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1157–1176.

  • 8.

    Doglioni C, Wotherspoon AC, Moschini A et al.. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992;339:834–835.

  • 9.

    Wyatt JI, Rathbone BJ. Immune response of the gastric mucosa to Campylobacter pylori. Scand J Gastroenterol 1998(suppl);142:44–49.

  • 10.

    Qin Y, Greiner A, Trunk MJ et al.. Somatic hypermutation in low-grade mucosa-associated lymphoid tissue-type B-cell lymphoma. Blood 1995;86:3528–3534.

  • 11.

    Wotherspoon AC, Doglioni C, Isaacson PG et al.. Regression of primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue after eradication of Helicobacter pylori. Lancet 1993;342: 575–577.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Chan JK. Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. Semin Diagn Pathol 1996;13:260–296.

  • 13.

    Thiede C, Wundisch T, Alpen B et al.. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001;19:1600–1609.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Ye H, Liu H, Attygalle A et al.. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H pylori in gastric MALT lymphoma. Blood 2003;102:1012–1018.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Streubel B, Simonitsch-Klupp I, Mullauer L et al.. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004;18:1722–1726.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Inagaki H, Nakamura T, Li C et al.. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004;28:1560–1567.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Levy M, Copie-Bergman C, Gameiro C et al.. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005;23:5061–5066.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Ye H, Dogan A, Karran L et al.. BCL10 expresion in normal and neoplastic tissue: nuclear localization in MALT lymphoma. Am J Pathol 2000;157:1147–1154.

  • 19.

    Farnha P, Gascoyne RD. Molecular pathogenesis of mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005;23:6370–6378.

  • 20.

    Starostik P, Patzner J, Greiner A et al.. Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct genetic pathways. Blood 2002;99:3–9.

  • 21.

    Rohatiner A, d'Amore F, Coiffier B et al.. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5:397–400.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Steinbach G, Ford R, Glober G et al.. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999;131:88–95.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Roggero E, Zucca E, Pinotti G et al.. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1995;122:767–769.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Bayerdorffer E, Neubauer A, Rudolph B et al.. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection: MALT Lymphoma Study Group. Lancet 1995;345:1591–1594.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Mogner A, Miehlke S, Fishbach S et al.. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001;19:2041–2048.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Steinbach G, Ford R, Glober G et al.. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1999;131:88–95.

  • 27.

    Liu H, Ye H, Ruskone-Fourmestraux A et al.. t(11;18) is a marker for all stage gastric MALT lymphomas that will not respond to H pylori eradication. Gastroenterology 2002;122:1286–1294.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998;16:1916–1921.

  • 29.

    Tsang RW, Gospodarowicz MK, Pintilie M et al.. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003;21:4157–4164.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    de Mascarel A, Ruskone-Fourmestraux A, Vavergne-Slove A et al.. Clinical, histological and molecular follow-up of 60 patients with gastric marginal zone lymphoma of mucosa-associated lymphoid tissue. Virchows Arch 2005;446:219–224.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Jager G, Neumeister P, Brezinschek R et al.. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol 2002;20: 3872–3877.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Martinelli G, Laszlo D, Ferreri AJ et al.. Clinical activity of rituximab in gatric marginal zone NHL resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005;23:1979–1983.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    O'Conner OA, Wright J, Moskowitz C et al.. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005;23:676–684.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Alpha-chain disease and related small intestinal lymphoma: a memorandum. Bull World Health Organ 1976,54:615–624.

  • 35.

    Isaacson PG. Gastrointestinal lymphoma. Hum Pathol 1994;25: 1020–1029.

  • 36.

    Ramot B, Shahin N, Bubis JJ. Malabsorption syndrome in lymphoma of small intestine: a study of 13 cases. Isr Med J 1965;47:221–226.

  • 37.

    Rambaud JC, Halphen M, Galian A, Tsapis A. Immunoproliferative small intestinal disease (IPSID): relationships with alpha-chain disease and ``Mediterranean'' lymphomas. Springer Semin Immunopathol 1990;12:239–250.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 38.

    Khojasteh A, Haghighi P. Immunoproliferative small intestinal disease: portrait of a potentially preventable cancer from the Third World. Am J Med 1990;89:483–490.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Lecuit M, Abachin E, Martin A et al.. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med 2004;350:239–248.

  • 40.

    Ben-Ayed F, Halphen M, Najjar T et al.. Treatment of alpha chain disease: results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer 1989;63:1251–1256.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 41.

    Akbulut H, Soykan I, Yakaryilmaz F et al.. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer 1997;80:8–14.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Garbe C, Stein H, Dienemann D et al.. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J Am Acad Dermatol 1991;24:584–590.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Cerroni L, Zochling N, Putz B, Kerl H. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J Cutan Pathol 1997;24:457–461.

  • 44.

    Roggero E, Zucca E, Mainetii C et al.. Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. Hum Pathol 2000;31:263–268.

  • 45.

    Ferreri AJ, Guidoboni M, Ponzoni M et al.. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst 2004;96:586–594.

  • 46.

    Ferreri AJ, Ponzoni M, Guidoboni M et al.. Regression of ocular adnexal lymphoma after Chlamydia psittaci-eradicating antibiotic therapy. J Clin Oncol 2005;23:5067–5073.

  • 47.

    Isaacson PG, Matutues C, Burke M et al.. The histopathology of splenic lymphoma with villous lymphocytes. Blood 1994;84: 3828–3834.

  • 48.

    Chacon JI, Mollefo M, Munoz E et al.. Splenic marginal zone lymphoma: Clinical characteristics and prognostic factors in a series of 60 patients. Blood 2002;100:1648–1654.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 49.

    Troussard X, Valenci F, Duchayne E et al.. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731–736.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Berger F, Felman P, Thieblemont C et al.. Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients. Blood 2000;95:1950–1956.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Audouin J, Le Tourneau A, Molina T et al.. Patterns of bone marrow involvement in 58 patients presenting primary splenic marginal zone lymphoma with or without circulating villous lymphocytes. Br J Haematol 2003;122:404–412.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 52.

    Hernandez JM, Garcia JL, Gutierrez NC et al.. Novel genomic imbalances in B-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics. Am J Pathol 2001;158:1843–1850

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Rosenwald A, Ott G, Stilgenbauer S et al.. Exclusive detection of the t(11:18)(q21;q21) in extra-nodal marginal zone B cell lymphomas (MZBK) of MALT type in contrast to other MZBL and extra-nodal large B cell lymphomas. Am J Pathol 1999;155:1817–1821.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 54.

    Sanchez-Izquierdo D, Buchonnet G, Siebert R et al.. MALT1 is deregulated by both chromosomal translocation and amplification in B-cell non-Hodgkins lymphoma. Blood 2003;101:4539–4546.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 55.

    Sole F, Salido M, Espinet B et al.. Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 2001;86:71–77.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Gruska-Westwood AM, Matutes E, Coignet LF et al.. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. Br J Haematol 1999;104:600–604.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Oscier DG, Gardiner A, Mould S. Structural abnormalities of chromosome 7q in chronic lymphoproliferative disorders. Cancer Genet Cytogenet 1996;92:24–27.

  • 58.

    Algara P, Mateo MS, Sanchez-Beato M et al.. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299–1304.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Mele A, Pulsoni A, Bianco E et al.. Hepatitis C virus and B cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003;102:996–999.

  • 60.

    Saadoun D, Suarez F, Lefrere F et al.. Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? Blood 2005;105:74–76.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 61.

    Vallisa D, Bernuzzi P, Arcaini L et al.. Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience. J Clin Oncol 2005;23:468–473.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 62.

    Catovsky D, Matutes E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999;36:148–154.

  • 63.

    Thieblemont C, Felman P, Callet-Bauchu E et al.. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95–103.

  • 64.

    Mulligan SP, Matutes E, Dearden C et al.. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 1991;78:206–209.

  • 65.

    Bolam S, Orchard J, Oscier D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1995;99:158–161.

  • 66.

    Lefrere F, Hermine O, Belanger C et al.. Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes. Leukemia 2000;14:573–575.

  • 67.

    Virchis A, Mehta A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br J Haematol 1998;100:609.

  • 68.

    Lefrere F, Hermine O, Francois S et al.. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000;40:113–117.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 69.

    Arcaini L, Orlandi E, Scotti M et al.. Combination of rituximab, cyclophosphamide, and vincristine induces complete hematologic remission of splenic marginal zone lymphoma. Clin Lymphoma 2004;4:250–252.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 70.

    Thomas D, O'Brian S, Cortes J et al.. Treatment of splenic lymphoma with villous lymphocytes (SLVL) and marginal zone lymphoma (MZL) with single agent Rituximab [abstract]. Blood 2001;98:134a.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 71.

    Nathwani BN, Anderson JR, Armitage JO et al.. Marginal zone B-cell lymphoma: a clinical comparison of nodal and mucosa-associated lymphoid tissue types: nNon-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1999;17:2486–2492.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 72.

    Sheibani K, Burke JS, Swartz WG et al.. Monocytoid B-cell lymphoma: clinicopathologic study of 21 cases of a unique type of low-grade lymphoma. Cancer 1988;62:1531–1538.

  • 73.

    Koh LP, Lim LC, Thng CH. Retreatment with chimeric CD 20 monoclonal antibody in a patient with nodal marginal zone B-cell lymphoma. Med Oncol 2000;17:225–228.

Copyright:
Copyright © 2006 by the National Comprehensive Cancer Network
Page Numbers:
8
Article Category:
Research Article
Received:
01 Nov 2005
Accepted:
22 Nov 2005
Print Publication Date:
01 Mar 2006
Online Publication Date:
Mar 2006
Keywords:
Marginal zone lymphoma; MALT lymphoma; splenic marginal zone lymphoma; nodal marginal zone lymphoma

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 1098 478 38
PDF Downloads 654 149 18
EPUB Downloads 0 0 0